Disclosed are a salt represented by formula (I), and a method for producing the salt, and a quencher and a resist composition comprising the same: ##STR00001## wherein R.sup.1 and R.sup.2 each represent a hydrocarbon group, and —CH.sub.2— included in the hydrocarbon group may be replaced by —O— or —CO—; R.sup.3, R.sup.4 and R.sup.5 each represent a halogen atom, an alkyl fluoride group or a hydrocarbon group, and —CH.sub.2— included in the hydrocarbon group may be replaced by —O— or —CO—; m3 represents an integer of 0 to 2, and when m3 is 2, two R.sup.3 may be the same or different from each other; and m4 and m5 represent an integer of 0 to 5, and when m4 and/or m5 is/are 2 or more, a plurality of R.sup.4 and/or a plurality of R.sup.5 may be the same or different from each other.

Disclosed are a salt represented by formula (I), and a method for producing the salt, and a quencher and a resist composition comprising the same: ##STR00001## wherein R.sup.1 and R.sup.2 each represent a hydrocarbon group, and —CH.sub.2— included in the hydrocarbon group may be replaced by —O— or —CO—; R.sup.3, R.sup.4 and R.sup.5 each represent a halogen atom, an alkyl fluoride group or a hydrocarbon group, and —CH.sub.2— included in the hydrocarbon group may be replaced by —O— or —CO—; m3 represents an integer of 0 to 2, and when m3 is 2, two R.sup.3 may be the same or different from each other; and m4 and m5 represent an integer of 0 to 5, and when m4 and/or m5 is/are 2 or more, a plurality of R.sup.4 and/or a plurality of R.sup.5 may be the same or different from each other.

The object of the present invention addresses a problem of providing a novel hydrogen storage material containing a metal-organic framework that can effectively store hydrogen. Hydrogen can be effectively stored by use of a hydrogen storage material containing a metal-organic framework, the metal-organic framework comprising a carboxylate ion of formula (I) and a multivalent metal ion, wherein the carboxylate ion and the multivalent metal ion are bound to each other. (In formula (I), X is an unsubstituted or substituted C2-C20 alkyl group, an unsubstituted or substituted alkenyl group, an unsubstituted or substituted alkynyl group, an unsubstituted or substituted alkoxy group, an unsubstituted or substituted alkenyloxy group, an unsubstituted or substituted alkynyloxy group, a benzyloxy group, an unsubstituted or substituted alkylsulfanyl group, an unsubstituted or substituted alkenylsulfanyl group, an unsubstituted or substituted alkynylsulfanyl group, an unsubstituted or substituted alkylamino group, an unsubstituted or substituted dialkylamino group, an unsubstituted or substituted alkenylamino group, an unsubstituted or substituted dialkenylamino group, an unsubstituted or substituted alkynylamino group, an unsubstituted or substituted dialkynylamino group, a phenyl group, a sulfanyl group or an unsubstituted or substituted alkoxycarbonyl group.)

##STR00001##

Provided herein are compounds useful in the treatment of bacterial infections, pharmaceuticals comprising the same, and methods of use and preparation thereof.

The invention includes 2-β-naphthyl-acetic acid derivatives, which are selective AKR1C3 inhibitors. In certain embodiments, the compounds of the invention are R-naproxen analogs. The invention further includes methods of treating cancer, such as prostate cancer and/or castration-resistant prostate cancer, using at least one compound of the invention.

The invention includes 2-β-naphthyl-acetic acid derivatives, which are selective AKR1C3 inhibitors. In certain embodiments, the compounds of the invention are R-naproxen analogs. The invention further includes methods of treating cancer, such as prostate cancer and/or castration-resistant prostate cancer, using at least one compound of the invention.

The present invention relates to novel crystalline forms of elafibranor.

The present invention relates to novel crystalline forms of elafibranor.

The present invention concerns a compound having the following formula (I): wherein: —A is in particular —N(R′.sub.a)—C(═O)—R, R′.sub.a being H or a (C.sub.1-C.sub.6)alkyl group, and R being preferably a group having the following formula (II): —X is in particular chosen from the group consisting of: —SO.sub.2—N(R′.sub.b)—, R′.sub.b being H or a (C.sub.1-C.sub.6)alkyl group, —N(R″.sub.b)—SO.sub.2—, R″b being H or a (C.sub.1-C.sub.6)alkyl group, —CO—NH—, and —NH—CO—, for use for the treatment of pathologies characterized by bronchoconstriction, such as asthma. ##STR00001##

This compound which has excellent solvent solubility and compatibility with a resin, and which can generate bases and radicals with high efficiency by being irradiated with active energy rays, is represented by formula (1), where, in formula (1), R.sub.1, R.sub.2, R.sub.3, R.sub.5 and R.sub.6 represent a hydroxy group or an alkoxy group; the R.sub.4's independently represent an organic group containing a thioether bond; R.sub.7 and R.sub.9 independently represent a hydrogen atom or an alkyl group with 1 to 4 carbons; R.sub.8 represents an alkylene group or an arylene group; and X represents an oxygen atom or a sulfur atom. A photopolymerization initiator can include said novel compound; and a photosensitive resin composition can include said photopolymerization initiator, from which a cured product can be obtained that has high sensitivity and no metal corrosion. ##STR00001##